We need to assign scores so that we have clear priorities if conflicts over resources arise. The committee has undergone several other administrative changes this year in response to more stringent guidelines from the National Cancer Institute and tougher auditing procedures by drug companies and other funding agencies. A primary reviewer is now assigned to each proposed study. Each study is presented to the full committee, at which point questions are directed to the reviewer and the principal investigator. The statistical sections of each study are reviewed by a member of the Cancer Center's Biostatistics Unit.
All protocols undergo a random audit every two years.
All cancer-related protocols should be accompanied by a summary sheet and sent to Cancer Center data manager Lorraine Meehan. The information provided through OncoLink should not be used for diagnosing or treating a health problem or a disease. It is not a substitute for professional care. If you have or suspect you may have a health problem, you should consult your health care provider.